<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22789" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hepatitis B Vaccine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hodgens</surname>
            <given-names>Alexander</given-names>
          </name>
          <aff>Lake Erie College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Marathi</surname>
            <given-names>Rachana</given-names>
          </name>
          <aff>University of Mississippi Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alexander Hodgens declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rachana Marathi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22789.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">The hepatitis B vaccine is a medication used to prevent hepatitis B infection, which can lead to chronic liver failure and hepatocellular carcinoma. This activity reviews the indications, action, and contraindications for the hepatitis B vaccine as a valuable agent in preventing hepatitis B infection. This activity will highlight the mechanism of action, adverse event profile, and other vital factors pertinent for healthcare team members in reducing the burden of hepatitis B on their patients and community.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the mechanism of action of the hepatitis B vaccine.</p></list-item><list-item><p>Describe the administration regimens of the hepatitis B vaccine.</p></list-item><list-item><p>Explain the monitoring for patients receiving the hepatitis B vaccine, including any toxicity.</p></list-item><list-item><p>Outline the importance of improving care coordination amongst the healthcare team to enhance care delivery for patients receiving the hepatitis B vaccine.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22789&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22789">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22789.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Public health officials have ranked the reduction in vaccine-preventable diseases as one of the top 10 public health achievements in the 21 century.<xref ref-type="bibr" rid="article-22789.r1">[1]</xref>&#x000a0;The hepatitis B vaccine is an integral part of this achievement, and its role continues to evolve this century. Hepatitis B vaccination is indicated to prevent active infection with the hepatitis B virus, which can lead to chronic liver failure and hepatocellular carcinoma. The virus is highly infectious and can transmit through percutaneous or mucosal exposure to blood and body fluids. The virus even remains viable on environmental surfaces for more than seven days.<xref ref-type="bibr" rid="article-22789.r2">[2]</xref></p>
        <p>The first hepatitis B vaccine received FDA approval for use in the United States in 1981, with a recombinant version coming to market in 1986 that replaced the original blood-derived vaccine.<xref ref-type="bibr" rid="article-22789.r3">[3]</xref> The immunization program for hepatitis B changed significantly in 1991 in the United States with a big push to eradicate the infection and substantially reduce its resultant morbidity and mortality. In 1991, the United States started a strategy to achieve universal vaccination of infants beginning at birth for hepatitis B.<xref ref-type="bibr" rid="article-22789.r2">[2]</xref>&#x000a0;The vaccine has numerous other indications. In addition to all infants and any yet unvaccinated children, the Advisory Committee on Immunization Practices recommends primarily vaccinating any adults who may have a higher risk for contracting or complication from hepatitis B, including any of the following[2]:</p>
        <list list-type="bullet">
          <list-item>
            <p>Persons at risk for sexually transmitted disease</p>
          </list-item>
          <list-item>
            <p>Incarcerated persons</p>
          </list-item>
          <list-item>
            <p>Persons whose sex partner is hepatitis B surface antigen (HBsAg) positive</p>
          </list-item>
          <list-item>
            <p>HBsAg positive household contacts</p>
          </list-item>
          <list-item>
            <p>Men who have sex with men</p>
          </list-item>
          <list-item>
            <p>Intravenous drug users</p>
          </list-item>
          <list-item>
            <p>Healthcare workers, dialysis patients</p>
          </list-item>
          <list-item>
            <p>Persons with diabetes aged 19 to 59 years old</p>
          </list-item>
          <list-item>
            <p>Persons with hepatitis C</p>
          </list-item>
          <list-item>
            <p>Travelers to countries endemic for hepatitis B</p>
          </list-item>
          <list-item>
            <p>Persons with HIV</p>
          </list-item>
          <list-item>
            <p>Persons with chronic liver disease</p>
          </list-item>
          <list-item>
            <p>All persons seeking protection from hepatitis B</p>
          </list-item>
        </list>
        <p>This strategy has been largely effective. The vaccination itself benefits not just the vaccinated but the entire community. The increasing immunization rate has shown to reduce morbidity and mortality from the virus.<xref ref-type="bibr" rid="article-22789.r1">[1]</xref>&#x000a0;From 2000 to 2014, the rate of acute hepatitis B infection in adults dropped by 50%.<xref ref-type="bibr" rid="article-22789.r1">[1]</xref>&#x000a0;This effect was mainly attributed to the herd immunity effect.<xref ref-type="bibr" rid="article-22789.r1">[1]</xref></p>
      </sec>
      <sec id="article-22789.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The vaccine is a non-infectious subunit of the virus, which leads to an active immunity. Antibodies produced by vaccination target the outer protein coat or surface antigen.&#x000a0;This leads to protection against all genotypes (A through H) of the virus and gives a broad immunity.<xref ref-type="bibr" rid="article-22789.r4">[4]</xref></p>
        <p>It is generally accepted that the hepatitis B vaccine confers lifelong&#x000a0;protection; originally, it was thought to only last around eight years, but more recent research has confirmed ongoing immunity for at least 25 years in those individuals who demonstrated a good immune response from the vaccine series.<xref ref-type="bibr" rid="article-22789.r5">[5]</xref><xref ref-type="bibr" rid="article-22789.r6">[6]</xref>&#x000a0;</p>
        <p>Patients who fail to develop a good response from the vaccine tend to be over 40 years of age, obese, have celiac disease, smoke tobacco, or misuse alcohol. This last group will especially be affected if they have progressed to liver disease.<xref ref-type="bibr" rid="article-22789.r7">[7]</xref><xref ref-type="bibr" rid="article-22789.r8">[8]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-22789.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Intramuscular injection is the preferred administration method. The intradermal route is not recommended. The preferred site of injection is the deltoid muscle. A regimen of three doses of the recombinant vaccine over six months is the current preferred method. A new vaccine has received approval for adults in the United States, which requires just two doses in one month.<xref ref-type="bibr" rid="article-22789.r1">[1]</xref><xref ref-type="bibr" rid="article-22789.r4">[4]</xref></p>
        <p>After completing the three vaccination series, patients may receive a blood test after one to four months to determine the immune response, which is defined as an anti-hepatitis B surface antigen (anti-Hbs) antibody level exceeding 100mIU/mL. An antibody response falling between 10 and 100 mIU/mL demonstrates an inadequate response; these patients should get a single booster shot, but do not require a retest. Responses below 10 mIU/mL require additional testing to check for prior hepatitis B infection, and these patients should receive another three-dose regimen with testing again at the&#x000a0;one to four-month mark. Continued failed response warrants may require more aggressive interventions, including intradermal administration, high-dose vaccine, or double dosing&#x000a0;of combination hepatitis A and hepatitis B vaccine. Should this fail, the patient will need hepatitis&#x000a0;B immunoglobulin upon any exposure to the hepatitis B virus.<xref ref-type="bibr" rid="article-22789.r8">[8]</xref><xref ref-type="bibr" rid="article-22789.r9">[9]</xref><xref ref-type="bibr" rid="article-22789.r10">[10]</xref></p>
      </sec>
      <sec id="article-22789.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Research has demonstrated the hepatitis B vaccine to be safe for all age groups.<xref ref-type="bibr" rid="article-22789.r11">[11]</xref>&#x000a0;From 1982 to 2004, over 70 million persons received at least one dose of the vaccine in the United States, with the most reported side effects being: injection site pain (3&#x000a0;to 29%) and temperature greater than 99.9&#x000b0;F (1&#x000a0;to 6%).<xref ref-type="bibr" rid="article-22789.r12">[12]</xref>&#x000a0;These effects occurred at similar rates with persons receiving a placebo.<xref ref-type="bibr" rid="article-22789.r12">[12]</xref>&#x000a0;However, the Institute of Medicine in 2011 did conclude that evidence supports a causal relationship between the vaccine and anaphylaxis in persons with hypersensitivity to yeast.<xref ref-type="bibr" rid="article-22789.r12">[12]</xref></p>
      </sec>
      <sec id="article-22789.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Hepatitis B vaccine is contraindicated in individuals with a history of hypersensitivity to any components of the vaccine or a yeast hypersensitivity.<xref ref-type="bibr" rid="article-22789.r12">[12]</xref><xref ref-type="bibr" rid="article-22789.r11">[11]</xref>&#x000a0;Therefore, persons with a history of serious adverse events, such as anaphylaxis, after a previous hepatitis B vaccination (including combination vaccines) should not receive any further doses. Of note, the vaccine is not contraindicated in persons with a history of Guillain-Barre syndrome, autoimmune disease, current pregnancy, or lactation. The vaccine contains a noninfectious surface antigen, which poses no risk of transmission to the fetus.<xref ref-type="bibr" rid="article-22789.r11">[11]</xref></p>
      </sec>
      <sec id="article-22789.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Hepatitis B surface antibody titers increase quickly following vaccination and then decrease over time.<xref ref-type="bibr" rid="article-22789.r1">[1]</xref>&#x000a0;More than 90% of immunized children develop protective antibody levels after the first dose.<xref ref-type="bibr" rid="article-22789.r12">[12]</xref><xref ref-type="bibr" rid="article-22789.r13">[13]</xref>&#x000a0;An immunocompetent person receiving the complete series is generally protected indefinitely. The Advisory Committee on Immunization Practices (ACIP) does not generally recommend titers after vaccination, except for some health care workers and immunocompromised persons.<xref ref-type="bibr" rid="article-22789.r1">[1]</xref>&#x000a0;In health care workers at risk for occupational exposure, serologic testing is recommended 1 to 2 months after the last vaccine dose, and revaccination with &#x02265;one dose is the recommendation for non-responders.<xref ref-type="bibr" rid="article-22789.r14">[14]</xref><xref ref-type="bibr" rid="article-22789.r13">[13]</xref>&#x000a0;</p>
        <p>Health care workers who completed the vaccine series and had a subsequent positive titer (&#x02265;10 mIU/mL anti-HBs) are considered hepatitis B immune and do not need any further routine testing for protection so long as they remain immune-competent.<xref ref-type="bibr" rid="article-22789.r14">[14]</xref>&#x000a0;All persons receiving the vaccine should remain under observation for at least 15 minutes following its administration for syncope or signs of anaphylaxis.<xref ref-type="bibr" rid="article-22789.r4">[4]</xref><xref ref-type="bibr" rid="article-22789.r12">[12]</xref><xref ref-type="bibr" rid="article-22789.r11">[11]</xref></p>
      </sec>
      <sec id="article-22789.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The vaccine is not known to have any dose-dependent toxicity, especially with newer nanoparticle formulations.<xref ref-type="bibr" rid="article-22789.r7">[7]</xref>&#x000a0;There is no antidote indicated for its management.</p>
      </sec>
      <sec id="article-22789.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The interprofessional health care team faces many challenges when vaccinating patients for hepatitis B. While few medical interventions have as significant an impact on health as vaccinations, and the hepatitis B vaccination is generally safe, lack of knowledge about the vaccine by healthcare team members and patient concern about adverse events can decrease coverage. Challenges on knowledge of the vaccine for healthcare team members include staying current on evolving recommendations for whom the vaccine is indicated.<xref ref-type="bibr" rid="article-22789.r1">[1]</xref><xref ref-type="bibr" rid="article-22789.r12">[12]</xref><xref ref-type="bibr" rid="article-22789.r15">[15]</xref>&#x000a0;All team members can increase the vaccination rate of their patients by encouraging all staff to become trained in the assessment of vaccination histories and any pertinent staff in the administration of the vaccine. Protecting the time available for the team to do this is an essential component of this strategy. All patients should receive education on the benefits of vaccination, including its herd immunity effect, the generally safe side effect profile, and the relatively few contraindications. A presumption of acceptance may be effective with most patients.<xref ref-type="bibr" rid="article-22789.r1">[1]</xref><xref ref-type="bibr" rid="article-22789.r15">[15]</xref>&#x000a0;The hesitant parent and patient who does not respond to this can pose a challenge in vaccination.<xref ref-type="bibr" rid="article-22789.r15">[15]</xref>&#x000a0;Motivational interviewing techniques have shown to be effective with these hesitant patients.<xref ref-type="bibr" rid="article-22789.r1">[1]</xref></p>
        <p>Nurses should always verify the patient's vaccination status regarding hepatitis B (as well as other vaccines) and report their findings to the clinician. Many states in the USA allow pharmacists to administer the vaccine, and pharmacists should reinforce the counsel from the provider and nursing staff and update the patient's record with each dose. In this manner, the entire interprofessional team can operate from the same data regarding vaccination status, leading to better patient outcomes. [Level 5]</p>
        <p>Of note, there is a new adjuvanted vaccination in development, now approved for adults in the United States for adults, which would reduce the time for series completion from a six-month 3-dose series to a one-month 2-dose series.<xref ref-type="bibr" rid="article-22789.r1">[1]</xref><xref ref-type="bibr" rid="article-22789.r16">[16]</xref><xref ref-type="bibr" rid="article-22789.r17">[17]</xref>&#x000a0;This development would carry the promise to reduce some of the burdens on patients, physician offices, and pharmacies of administering the vaccine series as well as increase vaccination rates.<xref ref-type="bibr" rid="article-22789.r1">[1]</xref><xref ref-type="bibr" rid="article-22789.r16">[16]</xref><xref ref-type="bibr" rid="article-22789.r17">[17]</xref></p>
      </sec>
      <sec id="article-22789.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22789&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22789">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22789/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22789">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22789.s11">
        <title>References</title>
        <ref id="article-22789.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hunter</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fryhofer</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Szilagyi</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Vaccination of Adults in General Medical Practice.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>95</volume>
            <issue>1</issue>
            <fpage>169</fpage>
            <page-range>169-183</page-range>
            <pub-id pub-id-type="pmid">31902413</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22789.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schillie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vellozzi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reingold</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Haber</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2018</year>
            <month>Jan</month>
            <day>12</day>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-31</page-range>
            <pub-id pub-id-type="pmid">29939980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22789.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <article-title>Hepatitis B vaccines: WHO position paper &#x02013; July 2017.</article-title>
            <source>Wkly Epidemiol Rec</source>
            <year>2017</year>
            <month>Jul</month>
            <day>07</day>
            <volume>92</volume>
            <issue>27</issue>
            <fpage>369</fpage>
            <page-range>369-92</page-range>
            <pub-id pub-id-type="pmid">28685564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22789.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roman&#x000f2;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Paladini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Galli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Raimondo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pollicino</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zanetti</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Hepatitis B vaccination.</article-title>
            <source>Hum Vaccin Immunother</source>
            <year>2015</year>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <page-range>53-7</page-range>
            <pub-id pub-id-type="pmid">25483515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22789.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petersen</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Bulkow</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>McMahon</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Zanis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Getty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Parkinson</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth.</article-title>
            <source>Pediatr Infect Dis J</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>23</volume>
            <issue>7</issue>
            <fpage>650</fpage>
            <page-range>650-5</page-range>
            <pub-id pub-id-type="pmid">15247604</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22789.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gabbuti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roman&#x000f2;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Blanc</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Meacci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Amendola</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mele</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mazzotta</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zanetti</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents.</article-title>
            <source>Vaccine</source>
            <year>2007</year>
            <month>Apr</month>
            <day>20</day>
            <volume>25</volume>
            <issue>16</issue>
            <fpage>3129</fpage>
            <page-range>3129-32</page-range>
            <pub-id pub-id-type="pmid">17291637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22789.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S</surname>
                <given-names>KRN</given-names>
              </name>
              <name>
                <surname>Nishanth</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>R S</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Nivedh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Syed</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>R</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Hepatitis B-surface antigen (HBsAg) vaccine fabricated chitosan-polyethylene glycol nanocomposite (HBsAg-CS-PEG- NC) preparation, immunogenicity, controlled release pattern, biocompatibility or non-target toxicity.</article-title>
            <source>Int J Biol Macromol</source>
            <year>2020</year>
            <month>Feb</month>
            <day>01</day>
            <volume>144</volume>
            <fpage>978</fpage>
            <page-range>978-994</page-range>
            <pub-id pub-id-type="pmid">31669465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22789.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Filippelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lionetti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gennaro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lanzafame</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arrigo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Salpietro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>La Rosa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leonardi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Hepatitis B vaccine by intradermal route in non responder patients: an update.</article-title>
            <source>World J Gastroenterol</source>
            <year>2014</year>
            <month>Aug</month>
            <day>14</day>
            <volume>20</volume>
            <issue>30</issue>
            <fpage>10383</fpage>
            <page-range>10383-94</page-range>
            <pub-id pub-id-type="pmid">25132754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22789.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cardell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Akerlind</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>S&#x000e4;llberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fryd&#x000e9;n</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine.</article-title>
            <source>J Infect Dis</source>
            <year>2008</year>
            <month>Aug</month>
            <day>01</day>
            <volume>198</volume>
            <issue>3</issue>
            <fpage>299</fpage>
            <page-range>299-304</page-range>
            <pub-id pub-id-type="pmid">18544037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22789.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levitz</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Regan</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Immunization with high-dose intradermal recombinant hepatitis B vaccine in healthcare workers who failed to respond to intramuscular vaccination.</article-title>
            <source>Infect Control Hosp Epidemiol</source>
            <year>1995</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>88</fpage>
            <page-range>88-91</page-range>
            <pub-id pub-id-type="pmid">7759824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22789.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Leary</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Maldonado</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Byington</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Update From the Advisory Committee on Immunization Practices.</article-title>
            <source>J Pediatric Infect Dis Soc</source>
            <year>2017</year>
            <month>Sep</month>
            <day>01</day>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>215</fpage>
            <page-range>215-218</page-range>
            <pub-id pub-id-type="pmid">28903515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22789.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <collab>Swedish Council on Health Technology Assessment</collab>
            <source>Vaccines to Children: Protective Effect and Adverse Events: A Systematic Review [Internet]</source>
            <publisher-name>Swedish Council on Health Technology Assessment (SBU)</publisher-name>
            <publisher-loc>Stockholm</publisher-loc>
            <year>2009</year>
            <month>02</month>
            <pub-id pub-id-type="pmid">28876765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22789.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'leary</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Maldonado</surname>
                <given-names>YA</given-names>
              </name>
              <name>
                <surname>Kimberlin</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Update From the Advisory Committee on Immunization Practices.</article-title>
            <source>J Pediatric Infect Dis Soc</source>
            <year>2019</year>
            <month>Dec</month>
            <day>27</day>
            <volume>8</volume>
            <issue>6</issue>
            <fpage>495</fpage>
            <page-range>495-500</page-range>
            <pub-id pub-id-type="pmid">31589289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22789.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schillie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Sawyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ly</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jiles</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Perio</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Reilly</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Byrd</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>JW</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention (CDC)</collab>
            </person-group>
            <article-title>CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2013</year>
            <month>Dec</month>
            <day>20</day>
            <volume>62</volume>
            <issue>RR-10</issue>
            <fpage>1</fpage>
            <page-range>1-19</page-range>
            <pub-id pub-id-type="pmid">24352112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22789.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Constable</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Caplan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Comparison of the implementation of human papillomavirus and hepatitis B vaccination programs in the United States: Implications for future vaccines.</article-title>
            <source>Vaccine</source>
            <year>2020</year>
            <month>Jan</month>
            <day>29</day>
            <volume>38</volume>
            <issue>5</issue>
            <fpage>954</fpage>
            <page-range>954-962</page-range>
            <pub-id pub-id-type="pmid">31843271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22789.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Splawn</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Medina</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Heplisav-B vaccination for the prevention of hepatitis B virus infection in adults in the United States.</article-title>
            <source>Drugs Today (Barc)</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>54</volume>
            <issue>7</issue>
            <fpage>399</fpage>
            <page-range>399-405</page-range>
            <pub-id pub-id-type="pmid">30090877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22789.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hyer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults.</article-title>
            <source>Vaccine</source>
            <year>2018</year>
            <month>May</month>
            <day>03</day>
            <volume>36</volume>
            <issue>19</issue>
            <fpage>2604</fpage>
            <page-range>2604-2611</page-range>
            <pub-id pub-id-type="pmid">29628151</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
